Gout and its comorbidities: implications for therapy

Area of Science:

• Rheumatology
• Internal Medicine
• Pharmacology

Background:

• Gout is a prevalent inflammatory arthritis.
• It frequently coexists with metabolic syndrome, hypertension, cardiovascular disease, renal impairment, diabetes, and hyperlipidaemia.
• Comorbidities and their treatments influence gout development and therapeutic choices.

Purpose of the Study:

• To review the intricate relationship between gout and its common comorbidities.
• To focus on gout treatment strategies in the context of comorbid conditions.
• To examine potential drug interactions between gout medications and treatments for comorbid diseases.

Main Methods:

• Literature review of existing studies on gout and comorbidities.
• Analysis of treatment guidelines and pharmacological data.
• Synthesis of information on therapeutic options and drug interactions.

Main Results:

• Corticosteroids may be a safer acute gout treatment than NSAIDs or colchicine in patients with renal/cardiac impairment.
• Sustained serum urate reduction below 0.36 mmol/l is key for long-term gout management.
• Optimal dosing for renal impairment and newer urate-lowering therapies require further investigation.

Conclusions:

• Gout management necessitates a comprehensive approach, considering patient comorbidities.
• Therapeutic decisions for gout must account for potential interactions with medications for coexisting conditions.
• Further research is needed to optimize gout treatment in complex patient populations, especially those with renal impairment.